{"id":"NCT01014208","sponsor":"GlaxoSmithKline","briefTitle":"Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma","officialTitle":"Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant (ASCT) in Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-03","primaryCompletion":"2014-02","completion":"2014-11","firstPosted":"2009-11-16","resultsPosted":"2014-10-16","lastUpdate":"2015-08-07"},"enrollment":447,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma, Large-Cell, Diffuse"],"interventions":[{"type":"DRUG","name":"OFATUMUMAB + DHAP","otherNames":[]},{"type":"DRUG","name":"RITUXIMAB + DHAP","otherNames":[]}],"arms":[{"label":"OFATUMUMAB + DHAP CHEMOTHERAPY REGIMEN","type":"EXPERIMENTAL"},{"label":"RITUXIMAB + DHAP CHEMOTHERAPY REGIMEN","type":"ACTIVE_COMPARATOR"}],"summary":"This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent disease, after first-line treatment with rituximab combined with an anthracycline-based chemotherapy regimen and be eligible for ASCT.","primaryOutcome":{"measure":"Progression-free Survival as Assessed by Independent Reviewers","timeFrame":"From randomization until the date of stable disease after two cycles of salvage chemotherapy, progression, or death (assessed for up to 5 years)","effectByArm":[{"arm":"Rituximab + Chemotherapy","deltaMin":2.14,"sd":null},{"arm":"Ofatumumab + Chemotherapy","deltaMin":1.81,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.333"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":7},"locations":{"siteCount":173,"countries":["United States","Argentina","Austria","Belgium","China","Czechia","Denmark","Estonia","Finland","Germany","Greece","Hungary","India","Ireland","Israel","Japan","Netherlands","Norway","Poland","Russia","Singapore","South Korea","Spain","Sweden","Thailand","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":115,"n":223},"commonTop":["Nausea","Anaemia","Thrombocytopenia","Fatigue","Vomiting"]}}